Investment Pitches

Pitch Summary:
High-quality global student placement and English testing platform temporarily marked down by regulatory headlines; trades ~13–14x depressed EBIT despite durable demand, pricing power, and share-gain opportunity as universities “flight to quality” for higher visa-approval candidates.

BSD Analysis:
IDP’s core engines—student placement into AU/UK/US/CA and co-ownership of IELTS—remain structurally sound; recent caps and policy noise have shocked near-term volumes, but history shows student flows redirect rather than disappear. As rules stabilize (Australia already softened; UK whitepaper avoided hard caps; US impact looks collateral), IDP should take share from fragmented agents because its pre-screening drives materially higher visa approvals (e.g., Canada 93% vs. ~55% industry) and better conversion—exactly what universities need under PAL/TAL quotas. Management can offset volume pressure with price (historically ~6%/yr) and mix, while ELT exposure is skewed to immigration-tied use-cases with higher inertia than newer entrants (e.g., DET). At ~13–14x trough EBIT with solid cash conversion, the market is pricing secular decline; a re-rating as sentiment normalizes plus mid-single-digit volume recovery and disciplined opex can rebuild EBIT toward ~$214m by FY29. Risks include further destination caps, prolonged negative sentiment in Canada, and test-share shifts (PTE/DET), but IDP’s brand, scale, and economics for universities underpin resilience.

Pitch Summary:
Blue Bird’s current earnings power appears unsustainably elevated and likely to reset lower as subsidy-driven EV demand fades and core bus replacement cycles weaken. Since 2022, federal and state programs—including the EPA’s Clean School Bus initiative along with California’s ZESBI and New York’s NYSBIP—have driven a surge in electric bus orders that carry roughly three times the revenue and disproportionately higher profit dollars than internal combustion models. With most of these subsidies now allocated and unlikely to be renewed, and as pandemic-era education funding expires, district budgets are tightening and order momentum is slowing. The company’s backlog now covers only about 1.5 quarters of deliveries, book-to-bill trends are below one, and year-to-date orders are down nearly 20%. These indicators suggest management’s mid-single-digit growth guidance is overly optimistic. As EV subsidies fade through FY26–FY27, mix and pricing benefits should unwind, competition should normalize, and margins should revert closer to pre-COVID levels. Historically, Blue Bird earned 7–8% EBITDA margins and ~$6–7k of EBITDA per bus versus today’s ~14–15% and ~$22k. A normalized view implies FY27 EBITDA around $90M (≈8.5% margin), over 60% below consensus. Applying an 8x multiple (in line with long-term averages) yields a ~$27 price target, or about 50% downside from current levels.

BSD Analysis:
Blue Bird’s recent results are inflated by one-time federal and state subsidies for electric buses that are nearing exhaustion, and underlying school district demand is weakening as COVID-era funding rolls off. Management turnover, aggressive insider selling, and shrinking backlogs corroborate a cyclical peak in both volumes and margins. As subsidy tailwinds fade, EBITDA should normalize toward historical levels, implying a sharp reset in earnings power and valuation. The stock trades as if current profitability is sustainable, but the coming decline in EV mix and district funding pressures suggest meaningful downside risk over the next 12–24 months.

Pitch Summary:
Global outsourced food services provider (#3 worldwide, #2 US) serving education, healthcare, corporate, and sports/leisure markets. Recurring, resilient revenues with 95% retention; only modestly cyclical (LSD decline in GFC). New CEO John Zillmer (post-activist Mantle Ridge intervention) shifted culture to sales/service, improving win rates (15% → 30%), retention (93.5% → 95%), and organic growth in line with Compass. Leverage post-COVID peaked at 16× but is falling toward 3×, creating capacity for buybacks. Potential consolidation with Sodexo remains optionality. Growth algorithm: ~6% organic growth, 40–50bps annual margin expansion, high-teens EPS CAGR.

BSD Analysis:
ARMK is a defensive growth story benefiting from secular outsourcing tailwinds, scale advantages, and improved management execution. With leverage normalized and capital return optionality unlocked, investors gain exposure to a sticky customer base and stable cash flows. Relative to Compass, valuation remains modestly discounted, offering ~57% upside to ~$62 by 2028. Risks include slower RTO trends, margin pressure from labor/food inflation, or regulatory hurdles in M&A, but downside is cushioned by recession-resistant contracts and mission-critical services.

Pitch Summary:
commercialization is further away than bulls expect and economics won’t justify today’s valuation. Highlights operational constraints and regulatory/timing risks on “driver-out.” Warns cash burn implies future capital raises/dilution.

BSD Analysis:
Kerrisdale’s short case on Aurora stresses the gap between management’s ambitious timelines and the entrenched difficulties of Level 4 autonomy. Despite a decade of R&D, Aurora has yet to demonstrate sustainable commercial deployment or clear unit economics. The thesis emphasizes structural headwinds: complex regulatory environments, safety validation hurdles, and massive ongoing capital requirements. Strategic partnerships with OEMs provide optics of credibility but limited near-term revenue, and management’s guidance assumes scaling that may prove unrealistic. Cash burn remains heavy relative to liquidity, with dilution risk looming. For investors, the asymmetry lies in Aurora being valued as a leader in a sector that may take years longer to commercialize than consensus assumes, leaving downside if investor patience wanes.

Pitch Summary:
The investment thesis for Acuren is based on the strategic merger with NV5, which is expected to unlock significant synergies and operational improvements. The merger aims to diversify revenue streams, reduce dependency on the oil and gas sector, and leverage complementary services for cross-selling opportunities.

BSD Analysis:
The merger between Acuren and NV5 is anticipated to yield $20 million in synergies, primarily through cross-selling and cost savings, although management considers this a conservative estimate. The integration of NV5's geospatial services with Acuren's drone business has already resulted in competitive wins. The merger also reduces Acuren's reliance on the oil and gas industry, now constituting only 22% of revenue, and enhances geographic diversification. Despite concerns over high net leverage, management's track record suggests a focus on deleveraging, similar to past successful strategies. The investment is risky, but the potential for Acuren to become a leading TIC and infrastructure company with stable cash flow is compelling.

Pitch Summary:
Fever-Tree is the global leader in premium mixers, offering tonic waters, ginger beers, and other cocktail mixers. I've admired Fever-Tree for nearly a decade but held back from investing due to its persistently high valuation. As an anecdote, during the March 2020 COVID sell-off, I put in a standing limit order to buy Fever-Tree shares, but even at the market bottom, my limit price was still below where shares traded, and our order never filled. However, late last year, an attractive opportunity emerged, leading us to initiate a position and eventually increase our investment as the thesis improved. Fever-Tree's historically high valuation reflected the company's rapid rate of growth, asset-light business model, and sustained high returns on invested capital. However, a recent combination of slowing growth and pandemic-related supply chain disruptions severely impacted Fever-Tree's profit margins, leading to a significant valuation reset. We purchased our position at what I consider ~13x "normalized" trailing earnings, which is well below the company's historical average P/E of about 65x. At our purchase price, the market implied that either the company would never grow again or it would never fix its margin issues. I believed it would do both. Founded in 2005, Fever-Tree was built on a straightforward insight that is captured well by its slogan: "If three-quarters of your drink is the mixer, mix with the best." While such product positioning seems obvious in hindsight, at that time, Schweppes dominated the mixer market with low-cost, artificially flavored, and highly sweetened drinks sold in large plastic bottles. Fever-Tree differentiated itself by focusing on ingredient quality–sourcing premium, natural ingredients, avoiding artificial flavors and sweeteners, and high-fructose corn syrup–qualities that resonated with customers. Before we continue, it's important to understand a nuance of the mixer industry that benefits Fever-Tree. Two years after Fever-Tree's launch, Cadbury Schweppes decided to break up its business and sell Schweppes' brand rights separately across multiple regions. As a result, the current geographic ownership of Schweppes is as follows: 1) Keurig Dr Pepper: United States and Canada 2) Coca-Cola: U.K., South America, and Eastern Europe 3) Suntory: Western Europe (France, Spain, Germany, Italy, the Nordics, etc.) 4) Asahi: Australia 5) Swire: China, Taiwan, and Hong Kong While this arrangement was financially attractive for Schweppes' sellers, the fragmented ownership structure proved a strategic mistake, preventing cohesive brand management and creating conflicts of interest that discouraged investment in the brand. No company wants to invest in initiatives that also benefit its competition. Ultimately, underinvestment in Schweppes transformed the dominant industry leader into a market share donor to premium brands like Fever-Tree and low-end private labels. Fever-Tree capitalized on this dynamic and is now the largest mixer brand by total value sold, though Schweppes remains the leader by volume. A lesser-known fact outside the beverage industry is that Coca-Cola is an asset-light business, owning minimal manufacturing and distribution infrastructure. Instead, the company uses a quasi-franchise system, granting exclusive territorial rights to bottlers who invest in infrastructure on Coca-Cola's behalf. This structure enables Coca-Cola to generate high returns on equity consistently. Undoubtedly inspired by Coke's success, Fever-Tree and many other beverage companies also adopt an asset-light approach, outsourcing production and distribution to third parties. However, unlike Coca-Cola, Fever-Tree doesn't solely depend on exclusive partners who manage both manufacturing and distribution. Instead, Fever-Tree often works with independent bottlers and distributors, often without long-term contractual commitments. Outside the United States, Fever-Tree relies on this non-exclusive outsourced model. In this structure, the company orchestrates all aspects of its supply chain and then takes a hybrid approach alongside distributors to secure shelf space and menu placements with retailers, bars, and restaurants. Fever-Tree earns product margins from each unit sold directly to retailers or its distributors. In the United States, however, Fever-Tree experienced a watershed moment in January 2025 when it formed an exclusive strategic partnership with Molson Coors. Under this agreement, Molson Coors agreed to take over all manufacturing, distribution, marketing, and selling responsibilities for Fever-Tree in the United States. In exchange for these exclusive rights, Fever-Tree receives a percentage of Fever-Tree USA's profits, resembling a royalty payment. I discuss the Molson Coors partnership in greater detail below. Fever-Tree management indicated interest in replicating similar exclusive partnerships in other regions outside the United States. Fever-Tree's business model–earning either royalty payments through Molson Coors, or higher-margin, asset-light beverage sales–results in significant cash generation and enjoys notable competitive advantages from its strong brand recognition and established distribution networks. The strength of Fever-Tree's business is evident in its financial results. From its IPO in 2014 through 2021, Fever-Tree delivered returns on invested capital between 25% and 45%, all while sales grew at a compound annual rate of 27%, expanding by 16 times over this period. From a customer perspective, Fever-Tree's growth is due to the benefits its products provide to all parties involved–consumers enjoy higher-quality drinks, retailers and bars earn increased profits per sale, and distributors benefit from higher margins per case. Despite recent moderation in growth rates, Fever-Tree's opportunities remain extensive, notably with continued U.S. growth of 9% in 2024, even though most spirit brands faced material revenue declines during this period. The Fever-Tree-Molson Coors agreement features guaranteed minimum royalty payments from 2025 to 2030–an uncommon contract clause that sharply improves the investment's risk-reward profile. Covering 90 percent of the royalties projected in a high-growth and margin-improvement scenario over the next five years, these guarantees offer Fever-Tree strong earnings visibility and bind Molson Coors to executing an ambitious growth plan. These "minimum guaranteed payments" are not a worst-case-scenario safety net, but rather an incentive Molson Coors used to secure the partnership. Per company materials, if we assume Fever-Tree's U.S. business earned a 6% adjusted EBITDA margin in 2024, the guaranteed minimum royalty payments through 2028 will increase U.S. adjusted EBITDA by ~5.8x, representing a 55% CAGR. If Fever-Tree's non-U.S. operations grow revenues just 2% a year with some modest margin improvement, consolidated EBITDA will compound ~20% per year from 2024 to 2028. Approximately 75% of that growth is locked in through Molson Coors' guaranteed payments, giving Fever-Tree high earnings growth visibility. Any outperformance–whether faster international growth or U.S. results above the guaranteed plan–could lift profits further. I believe the market does not fully appreciate the high likelihood of Fever-Tree's profit growth. In the beverages industry, securing a top-tier distribution partner can be a significant competitive advantage. Distribution is a key chokepoint in this industry because liquids are heavy, bulky, low-value, and high-turnover, making consistent availability nationwide difficult to achieve. In the United States, which is quite spread out, only five beverage companies achieved enough scale to build out high-volume distribution networks. Further, the constraints of limited delivery truck space, priority given to distributor-tied brands, and category-exclusive agreements reduce the number of beverage companies that can achieve national distribution. Coca-Cola, Pepsi, Keurig Dr Pepper, Anheuser-Busch, and Molson Coors control the five high-volume U.S. beverage distributors. For mixer brands evaluating national distribution options, Keurig Dr Pepper and Coca-Cola pose conflicts because each owns Schweppes in other regions, and Pepsi generally avoids alcohol-adjacent products. That leaves Anheuser-Busch and Molson Coors as the logical nationwide options. At the same time, only two mixer brands, Fever-Tree and Schweppes, are large enough to matter to these large beer networks. Between them, only Molson Coors has demonstrated a strong commitment to diversifying beyond beer and even renamed itself the Molson Coors Beverage Company in 2020 to signal its bigger ambitions. Fever-Tree found an ideal partner for its aims. After studying the beverage industry, I believe the three elements that increase the odds of lasting success are: a unique and desirable product, a highly recognizable brand, and a strong distribution advantage. Fever-Tree now holds all three keys, particularly in the U.S. market, strengthened by its partnership with Molson Coors. In January 2025, shortly after our initial investment, Fever-Tree signed an exclusive partnership agreement with Molson Coors. The partnership excited me because other exclusive distribution deals have unlocked significant shareholder value for beverage brands, such as Monster Beverage's 2014 tie-up with Coca-Cola and Celsius's 2022 agreement with Pepsi. While Fever-Tree's arrangement was structured similarly to these deals, it also had the added benefit of resolving its margin issues. Under the agreement, Molson Coors gains exclusive U.S. rights for Fever-Tree's product range, taking complete control of manufacturing, distribution, and sales. In return, Fever-Tree will earn royalties linked to Fever-Tree USA's profits. Molson Coors further aligned interests by acquiring an 8.5% equity stake in Fever-Tree. The partnership reshapes Fever-Tree's outlook by resolving its margin and operational issues by transitioning to Molson's manufacturing for U.S.-sold products, while simultaneously accelerating growth in its largest market, the United States. On this latter point, Molson Coors maintains more than 500,000 sales accounts, compared with the roughly 70,000 that Fever-Tree accessed through its earlier distributor: Southern Glazer's Wine & Spirits. A sevenfold expansion is unlikely, yet doubling or even tripling Fever-Tree's footprint–particularly in convenience stores and outlets without spirits licenses, where Southern Glazer's did not have a presence–is plausible. Longer term, the partnership can unlock additional growth via new product categories such as launching ready-to-drink cocktails, mocktails, and adult soft drinks, which all leverage Molson Coors' manufacturing and distribution expertise. Although I viewed Fever-Tree's partnership with Molson Coors as a watershed moment, its share price after the deal remained largely unchanged. The agreement elevated Fever-Tree's future growth rates, fundamentally improved the odds of margin recovery, and lowered risk through its contractual payment terms. Yet, sell-side analysts mainly demonstrated skepticism for the deal since it wouldn't contribute to incremental profits until 2026. While the market yawned, we substantially increased our position. This may surprise you, but most Fever-Tree products sold in the U.S. today are manufactured in Europe. In other words, Fever-Tree fills its bottles and cans in Europe, loads them onto shipping containers, and transports them across the Atlantic to reach customers in its largest market. While centralized European production simplified supply-chain management, this arrangement ultimately created substantial operational challenges. When COVID struck, transatlantic freight costs surged. Coupled with rising energy prices, driven by the war in Ukraine, glass and aluminum producers also passed through substantial price increases. Fever-Tree was particularly vulnerable to these changes, as nearly half of its cost of goods sold was made up of U.S. logistics costs, glass bottles, and aluminum cans. As a result, the company's gross margin fell sharply, from 50.5% in 2020 to 32.1% by 2023, compressing its ~20% adjusted EBITDA margin to just 5.7%, erasing most of its profitability. While Fever-Tree's revenue grew by 45% during this period, its earnings declined by -45%. Over the past few years, Fever-Tree restructured and hedged its aluminum and glass contracts, secured lower freight rates, developed new supplier relationships, and raised prices, all of which have begun to improve margins. We estimate Fever-Tree's U.S. business was roughly breakeven in 2023, and adjusted EBITDA margins improved modestly to mid-single digits in 2024. If accurate, this implies that the non-U.S. business currently generates an adjusted EBITDA margin in the mid-teens. If Fever-Tree can fix its U.S. margins, it resolves most of its profitability concerns, and the Molson Coors partnership offers a clear solution. By assuming all U.S. production, Molson Coors eliminates transatlantic freight costs and third-party bottling fees, while leveraging its scale and supply-chain expertise to reduce material costs like glass and aluminum. These changes will significantly improve Fever-Tree USA's profitability. Although Fever-Tree USA is shifting to a royalty model–with Molson Coors retaining a portion of the profits–the partnership's significantly improved profitability will allow Fever-Tree to earn a royalty approaching 20% of each bottle's sale price, which is equivalent to the 20% adjusted EBITDA margins it earned pre-COVID. This setup allows Fever-Tree to achieve higher returns on capital than it did historically because the deal eliminates all working capital investment required to run its U.S. operation. Fever-Tree will instead focus its investments in new product development, brand-building, and marketing. When evaluating the risks of this investment, my primary concern centers around broader demographic shifts rather than operational factors, particularly uncertainty around the long-term impact of declining alcohol consumption on Fever-Tree's terminal value. Despite recent industry challenges in this regard, Fever-Tree has continued growing, driven by trends such as the premiumization of spirits, preference for longer drinks, and increased demand for higher-quality ingredients. Additionally, Fever-Tree's popularity in mocktails and non-alcoholic contexts provides resilience amid evolving consumer preferences. Given Fever-Tree's strong medium-term earnings growth visibility, I can monitor these trends and determine if a change is necessary. While substantial uncertainty remains, today's pessimism about alcohol consumption trends could prove overstated. If Molson Coors continues to be creditworthy and Fever-Tree's non-U.S. business continues to improve its margins, Fever-Tree's EBITDA will likely double over the next three years. At our average entry price, our investment was purchased at a mid-to-high single-digit multiple of adjusted EBITDA, compared to the company's historical average LTM EBITDA multiple of 40x. The risk-reward of this investment is skewed in our favor.

BSD Analysis:
Bonsai Partners presents a compelling turnaround thesis on Fever-Tree, the global leader in premium mixers, purchased at an attractive ~13x normalized P/E versus its historical 65x average. The manager's investment thesis centers on two key catalysts: margin recovery from COVID-related supply chain disruptions and accelerated growth through the transformative Molson Coors partnership. The January 2025 exclusive U.S. distribution deal with Molson Coors provides guaranteed minimum royalty payments through 2030, covering 90% of projected high-growth scenarios and offering exceptional earnings visibility with 55% CAGR potential through 2028. This partnership addresses Fever-Tree's core operational challenge of manufacturing products in Europe for U.S. consumption, which created unsustainable freight and material costs during the pandemic. Molson Coors' 500,000+ sales accounts versus Fever-Tree's previous 70,000 through Southern Glazer's represents a potential 2-3x distribution expansion opportunity. The fragmented ownership of competitor Schweppes across multiple regions has created strategic underinvestment, allowing Fever-Tree to capture market share and become the largest mixer brand by value. With consolidated EBITDA expected to compound at ~20% annually through 2028 and the stock trading at mid-to-high single-digit EBITDA multiples versus historical 40x, the risk-reward profile appears highly favorable for this asset-light, high-ROIC business model.

Pitch Summary:
The author highlights LSBK as an overlooked post-conversion thrift with early-stage special-situation dynamics. Following the completed second-step conversion, activist investor Stillwell accumulated a 10% stake and filed a 13D, signaling potential governance pressure and improved capital allocation ahead. Although the bank cannot be sold for three years, buybacks could begin within roughly 12 months, opening the door for tangible capital return initiatives. The company screens cheaply at ~0.75x book value, despite recent ROE improvement toward 9% and a strong 15% Tier 1 ratio. Comparable thrifts in the Northeast have been acquired at around 1.5x tangible book, suggesting meaningful upside if fundamentals stabilize or improve. With limited institutional ownership and a small (~$100m) market cap, the author sees the setup as mispriced and positioned for a re-rating as activist involvement, operating momentum, and capital deployment unfold.

BSD Analysis:
Second-step conversions are historically fertile ground for outsized returns, primarily because freshly recapitalized franchises tend to be overcapitalized, underfollowed, and inefficient—conditions activists like Stillwell specialize in correcting. LSBK’s balance sheet strength (15% Tier 1) creates optionality, while its subscale footprint and modest ROE suggest ample low-hanging operational improvements. The thrift and mutual conversion universe has repeatedly been taken out at 1.3–1.6x TBV, implying structural scarcity value for small community banks once shareholder pressure aligns with improving profitability. The key question is whether LSBK can lift ROE consistently above high-single-digits; without this, valuation convergence is difficult even with activist involvement. Rate environment and funding pressures remain key risks—deposit betas are rising across small banks, and credit normalization could dent earnings. Still, with a clean capital base, limited competition for the stock, and a proven activist now involved, the asymmetric skew leans favorable so long as management discipline improves and capital return is executed.

Actual Post Content:
Interesting setup at recently converted mutual bank $LSBK. This special situation is still in the early stages, as the bank only just completed its second-step conversion. Shortly after, prominent banking activist Stillwell established a 10% stake and filed a 13D. His exact plans are not yet clear, but he has a long and successful track record in the space, having invested in numerous conversions at different stages with consistent success. While the bank cannot be sold for the next three years, buybacks could begin in about a year. In the meantime, Stillwell may become active, potentially taking a board seat and pushing for more disciplined capital allocation of the newly infused capital. Importantly, he is the only institutional shareholder with a meaningful stake, and his disclosure and possible activism could draw broader investor attention to the stock. This is a small regional bank with a ~$100m market cap, so its being overlooked just weeks after the second-step conversion is not surprising. The bank also looks fairly cheap, trading at around 0.75x BV with a 5–7% ROE, which improved to almost 9% in the most recent quarter. Its Tier 1 ratio stands at 15%. For context, comparable banks in the Northeast have been acquired at ~1.5x TBV over the last 12 months. If recent operational improvements prove sustainable, there is clear room for a re-rating here.

URL: https://x.com/InvestSpecial/status/1957368232685220312